¥í¥°¥¤¥ó¤·¤Æ¤µ¤é¤Ëmixi¤ò³Ú¤·¤â¤¦

¥³¥á¥ó¥È¤òÅê¹Æ¤·¤Æ¾ðÊó¸ò´¹¡ª
¹¹¿·ÄÌÃΤò¼õ¤±¼è¤Ã¤Æ¡¢ºÇ¿·¾ðÊó¤ò¥²¥Ã¥È¡ª

mixiÁí¹ç°åÎÅ¥»¥ó¥¿¡¼¥³¥ß¥å¤Î·ì±Õ¸¡ºº¡¢Ç¢»ÀÃÍ¡õ¾¤Ë¤Ä¤¤¤Æ¡£

  • mixi¥Á¥§¥Ã¥¯
  • ¤³¤Î¥¨¥ó¥È¥ê¡¼¤ò¤Ï¤Æ¤Ê¥Ö¥Ã¥¯¥Þ¡¼¥¯¤ËÄɲÃ
¤³¤ó¤Ë¤Á¤Ï¡££³£³ºÐ¡¡ÃË¡¡´û±ý¤Ê¤·¡£
·ì±Õ¸¡ºº¤Î·ë²Ì¤¬¼ê¸µ¤Ë¤¢¤ê¡¢¿§¡¹Ä´¤Ù¤Þ¤·¤¿¤¬ÀìÌçά¸ì¡¢Ã±°Ì¤Î°ã¤¤¡Ê¡©¡Ë¤Ç
Í×ÎΤòÆÀ¤Þ¤»¤ó¤Î¤Ç¶µ¤¨¤Æ²¼¤µ¤¤¡£

¤Þ¤º¡¢Urate¡¡¤È¤¤¤¤¤Î¤ÏÇ¢»ÀÃͤǹç¤Ã¤Æ¤ª¤ê¤Þ¤¹¤«¡©¤½¤ì¤òÁ°Äó¤È¤·¤Æ°Ê²¼

Urate¡¡£°¡¥£´£±¡Ê¢«·ë²Ì¡Ëmmol/L¡¡¡¡¡¡£°¡¥£²£±¡Ý£°¡¥£´£´¡Ê¢«Ê¿¶ÑÃÍ¡©¡Ë

¤Îɽµ­¤¬¤¢¤ê¤Þ¤¹¤¬¡ã¡Ê¡Ë¤Ï¤â¤Á¤í¤ó»ä¤ÎÊ䭤Ǥ¹¡ä¡¢¤³¤Î¿ôÃÍ¤ÏÆüËܤΰì·å¿ôÃͤÈÈæ³Ó¤·¤¿¾ì¹ç¡¢¤É¤³¤ËÃͤ·¤Þ¤¹¤«¡©


¾¤Ë¤â¿Õµ¡Ç½¡¢¹ü¡¢Ç¢¸¡ºº¡¢·ìÃæÀ®Ê¬¡©Åù¤¬¸¡ºº·ë²Ì¤¬¾å¤¬¤Ã¤Æ¤ª¤ê¡¢°Ê²¼¤Ïɸ½àÃͳ°¤Ç¡ú°õ¤¬¤Ä¤¤¤Æ¤¤¤¿¤â¤Î¤Ç¤¹¡£

<FBC>
RBC¡¡ ¡¡ 4.28¡¡¡¡¡¡ 1012/L¡Ê12¤Ï12¾èɽµ­¡Ë¡¡¡¡ ¡¡4.50¡Ý6.50
MCH¡¡ ¡¡ 33.2¡¡¡¡¡¡ £ð£ç ¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡ ¡¡¡¡¡¡27.0¡Ý32.0
Lymphocytes¡¡¡¡1.1¡¡ 109/L(9¤Ï9¾èɽµ­¡Ë ¡¡¡¡¡¡1.5¡Ý4.0

C-Reactive Protein 12 £í£ç/L ¡¡¡¡¡¡>5


¤Þ¤¿¿ôÃÍÆâ¤Ç¤Ï¤¢¤ë¤â¤Î¤Î¡¢Èæ³ÓŪÊФäƤ¤¤ë¤È»×¤¨¤¿·ë²ÌÎà¤Ç¤¹¡£

<FBC>
WBC¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡4.8¡¡¡¡¡¡109/L ¡¡¡¡¡¡ 4.0-11.0
MCV ¡¡¡¡¡¡ 96.0 fL ¡¡¡¡¡¡ 88.0-99.0¡¡
MCHC ¡¡¡¡¡¡34.6 g/dL ¡¡¡¡¡¡ 30.0-35.8
MPV ¡¡¡¡¡¡ 8.9 fL ¡¡¡¡¡¡ 6.5-20.0
Neutrophocytes ¡¡¡¡3.2 109/L ¡¡¡¡ ¡¡2.0-7.5
Eosinophils ¡¡¡¡0.1 109/L ¡¡¡¡¡¡ 0.1-0.4

<Bone Profile>
Alk.phos¡¡¡¡£µ£¹¡¡¡¡¡¡¡¡¡¡iu/L ¡¡¡¡ 30-130


ξ­¼ó¤Î¼ð¤ì¡¢Êâ¹ÔÉÔǽ¤Þ¤Ç¤Î·ãÄˡʭ΢¡¢ìû´Þ¤à¡Ë¤Ë¤è¤ê¼õ¿Ç¡¢¤è¤Ã¤Æ¼õ¤±¤¿·ì±Õ¸¡ºº¤Ç¤¹¡£Urate¡¡Íó¤Ë¤Ï°Ê²¼¤Îµ­ºÜ¤â¤¢¤ê¡¢¼«Ê¬¤ÎÀ¸³è½¬´·¤«¤é¤âÄËÉ÷ȯºî¡Ê½é¡Ë¤Ê¤Î¤«¤È»×¤Ã¤¿¤Î¤Ç¤¹¤¬¡¢D£ò¤ÏÄËÉ÷¤ÏÊÒ¦¤·¤«È¯ºî¤¬µ¯¤­¤Ê¤¤¤Î¤Ç°ã¤¦¡¢·ì±Õ¸¡ºº¼«ÂΤ«¤é¤Ï²¿¤Î°Û¾ï¤â¤Ê¤¯¡¢¾É¾õ¤Î¸¶°ø¤Ï¸ÂÄê¤Ç¤­¤Ê¤¤¡Êº£¤Î¤È¤³¤í¡Ë¤È¸À¤¤¤Þ¤¹¡£¤É¤¦¤¤¤Ã¤¿»ö¤¬Í½Â¬¤Ç¤­¤ë¤«¤ò¶µ¤¨¤Æ¤¤¤¿¤À¤±¤Þ¤¹¤È¹¬¤¤¤Ç¤¹¡£¤è¤í¤·¤¯¤ª´ê¤¤Ãפ·¤Þ¤¹¡£

Likelihood of gout increases at urate>or =0.42mmol/L.
For patients on urate lowering therapy,target level is>or=0.30mml/L(BSR2007)




¥³¥á¥ó¥È(9)

Ç¢»ÀÃͤǤ¹¡£
ÄËÉ÷¤¬É¬¤º¤·¤âÊÒÊý¤Ëȯ¾É¤¹¤ë¤È¤Ï¤«¤®¤ê¤Þ¤»¤ó¡£Ä̾ï¤Ï°ìÉô°Ì¤Ç¤¹¤¬¡£
¤Á¤Ê¤ß¤Ë¡¢Ç¢»ÀÃͤ¬Ä㤯¤Æ¤âÄËÉ÷ȯºî¤Ïµ¯¤³¤ê¤Þ¤¹¡£»²¹Í¤Þ¤Ç¤Ë¡£
¥»¥¤¥³ÅÄÃæ¤µ¤ó¡ä

¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤¹¡¢Ç¢»ÀÃͤǹç¤Ã¤Æ¤¤¤ë¤ó¤Ç¤¹¤Í¡£

¼«Ê¬¤ÇÄ´¤Ù¤¿¸Â¤ê¤Ç¤Ï¤ª¤Ã¤·¤ã¤ëÄ̤ꡢÊÒ¦ȯºî¤È¤â¸Â¤é¤Ê¤¤¤·¡¢Ç¢»ÀÃͤ¬Ä㤯¤Æ¤âȯºî¤Ïµ¯¤­¤ë¤È¤¢¤ê¤Þ¤·¤¿¡£
­¤Î¼ð¤ì¡¢Äˤߤ¬°ú¤¤¤¿¸å¡¢º£ÅÙ¤Ïɨ¡¢Éª¤È´ØÀá¤ËÄˤߤ¬½Ð¤¿¤¿¤á¡¢ºÆÅÙDr¤Ë¥¢¥Ý¤ò¼è¤ê·ì±Õ¸¡ºº·ë²Ì¤òƧ¤Þ¤¨Ïäò¤·¤¿¤Î¤Ç¤¹¤¬¡¢¾åµ­¤Î¤è¤¦¤Ë°ì½³¤µ¤ìÀìÌçDr¤Ë¾Ò²ð¤â¤·¤Æ¤â¤é¤¨¤Þ¤»¤ó¤Ç¤·¤¿¡£

ÄËÉ÷¤Ç¤â¤Ê¤¯¡¢²¿¤â°Û¾ï¤¬Ìµ¤¤¤È¸À¤ï¤ì¤ì¤Ð¤½¤ì¤Þ¤Ç¡¢¸å¤Ï¼«Ê¬¤ÇÄËÉ÷¤òµ¿¤¤¡©µ¤¤ò¤Ä¤±¤ÆÀ¸³è¤·¤Æ¤¤¤¯¤·¤«Ìµ¤¤¤«¤È»×¤¤¡¢°ì±þÆüËܤΰì·å¿ôÃͤȤÎÈæ³Ó¤òÃΤꤿ¤«¤Ã¤¿¤Î¤Ç¤¹¤¬¡¦¡¦¡¦¶²¤é¤¯¤É¤Ê¤¿¤âÈæ³Ó¤Ç¤­¤Ê¤¤¡¢¤È¤¤¤¦»ö¤Ê¤Î¤Ç¤·¤ç¤¦¤Í¡£

Urate¤¬Ç¢»ÀÃÍ¡¢¤È¤¤¤¦»ö¤À¤±¤Ç¤â¶µ¤¨¤Æ¤¤¤¿¤À¤¤¤Æ½õ¤«¤ê¤Þ¤·¤¿¡£
¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤·¤¿¡ª
·ì±Õ¸¡ºº¤Î·ë²Ì¤Ê¤ó¤Æ¡¢¤¢¤¯¤Þ¤Ç¤½¤Î»þ¤À¤±¤Î¾õÂ֤οôÃͤʤΤǡ¢
Ç¢»ÀÃͤ¬¹â¤¯¤Ê¤¤¤«¤éÂç¾æÉס¢¤Ç¤Ï¤Ê¤¯¤¿¤Þ¤¿¤Þ¤À¤Ã¤¿¤È
¹Í¤¨¤ÆÀ¸³è¤·¤Þ¤·¤ç¤¦¡£
¤¦¡Á¤Á¤ã¤ó¤µ¤ó¡ä

¤½¤¦¤Ç¤¹¤Í¡¢¤¤¤º¤ì¤Ë¤·¤íÂλéËäòÍî¤È¤¹¤è¤¦¤ÊÀ¸³è¤ò¿´¤¬¤±¤Þ¤¹¡ªÌ¤¤À¤Ë¤¢¤Á¤³¤Á´ØÀ᤬Äˤߡ¢½èÊý¤µ¤ì¤¿ÄÃÄ˺ޤò£±¥ö·î°Ê¾å°û¤ß³¤±¤Æ¤¤¤ë¤Î¤¬µ¤¤Ë¤Ê¤ê¤Þ¤¹¤¬¡¦¡¦¡¦¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤¹¡ª

mayu¤µ¤ó¡ä

ÊÑ´¹¤¬½ÐÍè¤ë¤ó¤Ç¤¹¤Í¡ÊÅö¤¿¤êÁ°¤«¡ËÁǿͤʤâ¤Î¤Ç¡¢mEq¡¿£ì¤¬°ì·å¿ôÃͤÎñ°Ì¤È¤¤¤¦»ö¡©¤Ç¤¹¤Í¡£¤¿¤À¿ô»ú¤Ë¼å¤¯¼«Ê¬¤ÇÊÑ´¹¤Ç¤­¤Þ¤»¤ó¤Ç¤·¤¿¡Ê´À¡¡¤´ÃúÇ«¤Ë¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤·¤¿¡ª
ÆüËܤÎÇ¢»ÀÃͤÎñ°Ì¤Ã¤Æmg/dl¤¸¤ã¤Ê¤«¤Ã¤¿¤Ã¤±¡©¤È»×¤Ã¤¿¸µ¸¡ººµ»»Õ¤Ç¤¹¡£
ñ°Ì¤ÎÊÑ´¹ÊýË¡¤Ï³ØÀ¸»þÂå¤Ë½¬¤Ã¤¿¤è¤¦¤Êµ¤¤¬¤¹¤ë¤â¤Î¤Î¡¢Ëº¤ì¤Þ¤·¤¿¡Ä

¥í¥°¥¤¥ó¤¹¤ë¤È¡¢¤ß¤ó¤Ê¤Î¥³¥á¥ó¥È¤¬¤â¤Ã¤È¸«¤ì¤ë¤è

mixi¥æ¡¼¥¶¡¼
¥í¥°¥¤¥ó¤·¤Æ¥³¥á¥ó¥È¤·¤è¤¦¡ª

mixiÁí¹ç°åÎÅ¥»¥ó¥¿¡¼ ¹¹¿·¾ðÊó

mixiÁí¹ç°åÎÅ¥»¥ó¥¿¡¼¤Î¥á¥ó¥Ð¡¼¤Ï¤³¤ó¤Ê¥³¥ß¥å¥Ë¥Æ¥£¤Ë¤â»²²Ã¤·¤Æ¤¤¤Þ¤¹

À±°õ¤Î¿ô¤Ï¡¢¶¦Ä̤·¤Æ»²²Ã¤·¤Æ¤¤¤ë¥á¥ó¥Ð¡¼¤¬Â¿¤¤¤Û¤ÉÁý¤¨¤Þ¤¹¡£